zyme that methylates noradrenaline into adrenaline.
Introduction
Adrenal medullary cells are endocrine cells embryologically derived from the neural crest, which synthesize and release catecholamines. They are composed of adrenaline chromaffin cells and noradrenaline chromaffin cells with minor populations of small intensely fluorescent cells and ganglionic neurons (1) . Both adrenaline and noradrenaline chromaffin cells express catecholamine synthesizing enzymes, tyrosine hydroxylase (TH) and dopamine β-hydroxylase (DBH). Adrenaline cells, but not noradrenaline cells, have phenylethanolamine-N methyl transferase (PNMT), an envariety of peptides including chromogranins, opioid peptides and neuropeptide Y (6, 7) , which have unique functions such as regulating catecholamine release (8) , regulating antibacterial activity (9) , sorting peptides from the trans-Golgi network to dense core secretory granules (10) , and regulating cell adhesion (11) .
Catecholamines and other constituents in the chromaffin granules from chromaffin cells are released by pathophysiological stress. Hypoglycemia, hemorrhage, cold exposure or hypoxia causes exocytotic release directly via activation of chromaffin cells, as well as indirectly via activation of the preganglionic sympathetic fibers innervating chromaffin cells (1) .
On the other hand, adrenomedullin (AM) is a hypotensive peptide that was originally identified in human pheochromocytoma by monitoring of its action on 3 ,5 -cyclic adenosine monophosphate (cAMP) in platelets (12) . The AM level in plasma is altered in various diseases; for example, it is increased in patients with hypertension and normalized by anti-hypertensive therapy, indicating that AM is involved in protection against injury occurring in various pathological conditions (13, 14) . The precursor of AM, the preproAM gene, also produces another hypotensive peptide, the proadrenomedullin N-terminal 20 peptide (PAMP20) (15) . However, the mechanisms of action of these peptides are different. In the perfused rat mesenteric arteries, AM directly dilates vascular smooth muscle via receptor that reacts with calcitonin gene-related peptide (CGRP) (16) , whereas PAMP20 inhibits noradrenaline release from sympathetic nerve endings, resulting in vasodilatation (17) .
These peptides are produced not only in pheochromocytoma, but also in almost all organs of the body, and regulate a variety of cell functions (18) . Because, among normal tissues, these peptides are most abundantly present in the adrenal medulla, this review focuses on the regulation of expression of the AM and PAMP20 family as well as those functions under pathological states in adrenal chromaffin cells.
Expression and Release of AM and PAMP20 from Adrenal Chromaffin Cells
Studies have shown that the levels of immunoreactive (ir)-AM and ir-PAMP20 in the human adrenal medulla are more than 10 times higher than the already high concentrations in the atrium or pancreas (19) (20) (21) . AM in the adrenal medulla is synthesized by processing from preproAM via proAM, and the major ir-AM found in human adrenal medulla is mature AM. Although AM and PAMP20 are produced from the same gene, the level of ir-PAMP20 is lower than that of ir-AM in the adrenal medulla (22, 23) . This finding led us to seek novel PAMP20-related peptides in the adrenal medulla. By using an antibody recognizing the C-terminal structure of PAMP20, it was found that a high level of PAMP12, a 12 amino acid peptide identical to PAMP20 at amino acids 9-20, was present in pigs and cows (24, 25) . In addition, a considerable level of PAMP16, a peptide identical to PAMP20 at amino acids 5-20, was identified in the bovine adrenal medulla (24) . Therefore, PAMP20, PAMP12 and PAMP16 constitute a family of PAMP peptides.
ir-AM, ir-PAMP20 and catecholamines are released by stimulation of nicotinic cholinergic receptors of cultured bovine adrenal chromaffin cells with similar concentrationand time-dependent curves (26, 27) . The molar ratio among ir-AM, ir-PAMP20 and catecholamine release has been shown to be equivalent to the ratio found in the cells (26, 27) . In addition, the elution patterns on high performance liquid chromatography (HPLC) for ir-AM and ir-PAMP20 released into the medium are the same as those found in chromaffin cells (24, 26, 27) . Thus, AM and PAMP20 are stored in and released from chromaffin cells by exocytosis along with catecholamines.
ir-AM and ir-PAMP20 are also released gradually during culture of the bovine chromaffin cells (28) . This gradual release of ir-AM and ir-PAMP was increased by a membrane permeable analog of cAMP, dibutyryl cyclic AMP (dbc-AMP). The release of these peptides by dbcAMP was similar to that of catecholamines and chromogranin B, a marker peptide contained in chromaffin granules. In addition, AM mRNA was decreased by dbcAMP. These changes induced by dbcAMP were attenuated by H89, an inhibitor of cAMPdependent protein kinase, indicating that a cAMP-dependent protein kinase pathway stimulates the gradual release of these peptides via an exocytotic mechanism and decreases their synthesis via the reduction of their transcription level.
Although adrenal medulla synthesizes and releases high levels of AM and PAMP20, this tissue is unlikely to be the major source for these peptides in the blood. The AM concentration in the adrenal vein is not different from that in the aorta, and the AM level in the plasma is not higher in patients with pheochromocytoma, whose plasma catecholamine level is markedly elevated (29) . In addition, it has been reported that plasma AM levels were not changed significantly in patients with insulin-induced hypoglycemia, where plasma adrenaline levels were significantly increased (30) . Therefore, these peptides released from the adrenal medulla are unlikely to act as circulating hormones.
Vascular endothelial and smooth muscle cells in various tissues produce and release a high level of AM (31, 32) , and these cells may be the major source of plasma AM. In this regard, it is interesting to note that, in rats, AM production by brain endothelial cells is very high, and AM plasma concentration in the jugular vein is 50% higher than that in the vena cava (33) .
Hypoxia occurs in various physiological and pathological conditions, such as embryogenesis, labor, wound repair and carcinogenesis, and causes various responses, including activation of the sympathetic nervous system, hormone release and activation of gene expression. Under hypoxia, oxygen sensitive mechanisms activate gene expression of a variety of types of proteins, including differentiation factors, growth factors, enzymes and transporters such as erythropoietin, glucose transporter, heme oxygenase 1, vascular endothelial growth factor (VEGF), endothelin, and heat shock proteins (34, 35) . Therefore, in a recent study, we examined whether AM expression changed under a hypoxic condition in bovine chromaffin cells.
Hypoxia (1% O2) increased the accumulation of ir-AM in the medium, whereas reciprocally decreased their cellular content ( Fig. 1) . The catecholamine level in the medium increased, whereas the cellular content of catecholamine decreased under hypoxia, indicating that hypoxia caused exocytotic release of AM along with catecholamine. The total amount of AM in the medium plus that in cells increased under hypoxia. The AM mRNA level increased 4-fold under hypoxia, indicating that hypoxia stimulated AM release and synthesis via an increase of its transcript level.
The adrenal gland is a highly vascularized organ, and its blood flow is regulated by autonomic innervation as well as 
cells/dish) were cultured under normoxic (N) (20% O2) or hypoxic (H) (1% O2) conditions for the periods indicated on the horizontal axis, and ir-AM (a, b) and catecholamines (c, d) in the medium (a, c) and cells (b, d) were measured by radioimmunoassay and by HPLC coupled with electron chemical detection, respectively. Data are the mean SEM of three independent experiments. The AM mRNA level in the cells cultured under hypoxia for the indicated times was analyzed by Northern blotting (e). Poly A RNA prepared from 200 µg of total RNA was separated by 2% agarose gel, transferred to a nylon membrane and hybridized with a probe for AM or glyceraldehyde 3-phosphate dehydrogenase (GAPDH). AM mRNA was identified as a major band of 1.6 kb with a band of 2.5 kb. The mRNA level increased 4-fold under hypoxic condition at 12 h of hypoxia.
by nitric oxide, endothelin, and many other factors. Since AM increased blood flow in the isolated adrenal gland in situ and in the intact adrenal gland in vivo, this increased release by hypoxia may play a role in protecting against hypoxia of the adrenal gland. In addition, AM may facilitate the transport of catecholamines and other substances released from the adrenal gland to systemic circulation under hypoxia (36, 37) .
The expression of AM changes during cell differentiation. In contrast to adrenal chromaffin cells, most neurons express little AM (21, 38) . Therefore, we next examined how AM expression is regulated by neuronal differentiation using rat pheochromocytoma PC12 cells (Fig. 2) . When PC12 cells were differentiated by nerve growth factor (NGF), AM accumulation in the cell and medium decreased with neuronal differentiation. The AM mRNA level was also decreased by NGF, indicating that NGF decreases the expression of AM with neuronal differentiation.
Receptors for AM and PAMP20 in Adrenal Chromaffin Cells
The data about receptors for AM and PAMP20 in adrenal chromaffin cells are not consistent. ]AM have been detected by autoradiography in the rat adrenal medulla, and have been shown to be displaced by low concentrations of AM, AM or CGRP with similar potency, suggesting that AM reacts with receptors which recognize both AM and CGRP (41) . An abundance of [ 125 I]AM-binding sites have also been detected in the membrane fraction of the rat adrenal medulla (42) . These sites were of high affinity with a Kd of 3.64 nmol/l and were displaced only by AM, but not by CGRP, indicating that the receptors were specific to AM. Thus, the affinity and selectivity were different among these studies.
To date, three putative G protein-coupled receptors for AM have been cloned: L1 as an AM selective receptor (43); RDC-1 as a CGRP receptor that also reacts with AM (44); and calcitonin receptor-like receptor (CRLR), which requires co-expression of receptor-activity-modifying protein (RAMP) for its receptor activity (45) . The expression of CRLR with RAMP2 or RAMP3 produces an AM receptor, while the combination of CRLR and RAMP1 produces a CGRP receptor (45) . However, the identity of L1 and RDC-1 as receptors for AM or CGRP has been questioned (46, 47) . According to the CRLR-RAMP hypothesis, the difference of the selectivity to the binding sites might become clear by studying the expression of each RAMP in human and rat chromaffin cells.
Renshaw 
Fig. 2. Decrease in AM expression in PC12 cells differentiated by NGF. PC12 cells (1 10 6 cells/dish) were cultured in the absence or presence of 2.5s NGF (50 ng/ml) for 2 days, and ir-AM (a) was measured by radioimmunoassay. Note that the differentiation by NGF reduced ir-AM level both in the medium and cells. mRNA levels were analyzed by RT-PCR using primers amplifying 589 bp of rat AM sequence (145-733 of D15069) and 687 bp of rat GAPDH sequence (207-893 of M17701).
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[
125 I]PAMP-binding sites in the membrane of the rat adrenal medulla (50) . [ 125 I]PAMP-binding sites have also been demonstrated in the human adrenal medulla by autoradiography (51), and these sites were shown to be displaced by low concentrations (IC50 value of nanomolar order) of PAMP20 and PAMP [12] [13] [14] [15] [16] [17] [18] [19] [20] , but not by AM (52) . However, these high-affinity binding sites may not correlate with the regulated exocytosis and synthesis of catecholamines, in which the IC50 value for PAMP20 was of micromolar order (24, 26) .
Functions of AM, PAMP20 and PAMP12 in
Adrenal Chromaffin Cells AM, at nanomolar concentrations, has been shown to gradually release a small amount of catecholamine in human and rat adrenal medulla slices (41, 53) . This AM-induced catecholamine release was abolished by H-89 (41, 53) , suggesting that the gradual release of catecholamine in human and rat adrenal medullary slices following AM treatment may be mediated via a cAMP-dependent protein kinase pathway. In our previous study, however, we were unable to detect the effect of AM on catecholamine release from the bovine adrenal chromaffin cells (39 45 Ca 2 from cells through its stimulatory effect on membrane Na /Ca 2 exchanger in cultured bovine adrenal chromaffin cells (54) .
In addition, neither AM nor AM had any effect on either basal catecholamine release, catecholamine release induced by electrical stimulation of the splanchnic nerve, or catecholamine release induced by acetylcholine injection into the phrenico-abdominal artery of dogs, indicating that AM does not play a significant role in the regulated exocytosis of catecholamine in adrenal chromaffin cells (55) .
AM plays a role in the prevention of apoptosis of many cell types, including vascular endothelial cells, but in our previous study we did not observe a suppressive effect of AM on the apoptosis of PC12 cells caused by serum deprivation (unpublished data). Therefore, these data may suggest that the role of AM in chromaffin cell function is not extensive, though AM may play a role in the regulation of vascular tone to facilitate transport of hormones released in the adrenal gland to the systemic circulation and to protect from ischemic injury of the gland.
On the other hand, PAMP20 and PAMP12 modify the regulated exocytosis of catecholamine from the cells. In cultured bovine adrenal chromaffin cells, PAMP20 and PAMP12, with an IC50 of about 0.1 µmol/l, inhibited 22 Na influx caused by the stimulation of nicotinic cholinergic receptors in a non-competitive manner, thereby reducing 45 Ca 2 influx via voltage-dependent Ca 2 channels and catecholamine release with similar potency (24, 26) . These peptides did not alter high K -induced 45 Ca 2 influx via voltagedependent Ca 2 channels, veratridine-induced 22 Na influx via voltage-dependent Na channels, or catecholamine release evoked by histamine, indicating that PAMP20 and PAMP12 have anti-nicotinic properties, but do not act directly on voltage-dependent Ca 2 channels, voltage-dependent Na channels or histamine receptors (24, 26) .
Physiological experiments have also shown that the site of action of PAMP20 is nicotinic receptors (56) . PAMP20 inhibited both ionic currents and the increase in [Ca 2 ]i induced by nicotinic receptor stimulation. However, PAMP20 did not affect on increase in [Ca 2 ]i induced by the depolarization with high K . PAMP20 facilitated the desensitization process of the nicotine-induced ion currents. These effects of PAMP20 are not mediated by cAMP, because PAMP did not increase cAMP in the rat adrenal medulla (50) or in bovine adrenal chromaffin cells (unpublished data).
PAMP20 also suppressed catecholamine release from the human adrenal medulla, but the action was different from that observed in bovine adrenal chromaffin cells (52) . PAMP20 suppressed catecholamine release caused by activation of voltage-dependent Ca 2 channels by BayK-8644 or by high K , and by the stimulation of angiotensin II receptors with an IC50 value of 0.1 nmol/l, which was three or four orders lower than the value for suppression of catecholamine release caused by nicotinic receptor stimulation in bovine chromaffin cells or in PC12 cells (24, 57) . PAMP20 appears to inhibit Ca 2 -dependent, agonist-stimulated catecholamine secretion, acting via specific receptors and through a mechanism involving the impairment of Ca 2 influx in humans. An inhibitory effect of PAMP20 on nicotinic receptor activated catecholamine release has also been observed in in vivo experiments using dogs (55) . Catecholamine overflow from the adrenal gland caused by splanchnic nerve stimulation or by acetylcholine injection was suppressed by PAMP20. PAMP20 preferentially suppressed the catecholamine release caused by the nicotinic receptor activation that caused by the muscarinic receptor activation. Thus, PAMP20, but not AM, acts as an inhibitory regulator of adrenal catecholamine release in vivo by acting mainly on nicotinic cholinergic receptors.
PAMP20 also inhibits nicotinic cholinergic receptors in PC12 cells (57) . PAMP20 inhibited catecholamine release stimulated by nicotine in a non-competitive manner. PAMP20 failed to inhibit catecholamine release caused by high K , BaCl2, calcium ionophore (A23187), purinergic receptor agonist (adenosine 5 -triphosphate, ATP), or alkalinization of the vesicle core (chloroquine). In addition, PAMP completely abolished nicotine-induced influx of 45 Mahata et al. used PC12 cells to investigate which parts of the structure of PAMP20 were responsible for the inhibition of nicotinic receptors. N-terminal truncation of PAMP20 up to the 12th amino acid did not impair PAMP20 activity, but PAMP [16] [17] [18] [19] [20] lost its activity. A peptide without the C-terminal amide structure of PAMP20 showed weak activity, whereas a peptide truncated C-terminal of three amino acids showed no activity. Thus, the essential structures for PAMP action are the C-terminal amide structure and the C-terminal 8 amino acids (WNKWALSR-amide), and the latter region is likely to be an α-helical structure (57) .
The Gi α subunit of a member of the trimeric G protein family is not involved in the PAMP20-mediated suppression of catecholamine release caused by nicotinic stimulation of PC12 cells and chromaffin cells (57) . The PAMP-mediated suppression of catecholamine release caused by nicotinic receptor stimulation was not affected by pertussis toxin (PTX) pre-treatment in undifferentiated PC12 cells that express mainly L-type Ca 2 channels, in PC12 cells differentiated with NGF that express N-type Ca 2 channels (57), or in bovine chromaffin cells (unpublished data).
In addition to their effect on catecholamine release, PAMP20 family peptides also affect catecholamine synthesis. PAMP20 and PAMP12 did not affect basal catecholamine synthesis from tyrosine in cultured bovine adrenal chromaffin cells, but they suppressed the stimulatory effect of catecholamine synthesis caused by nicotinic receptor stimulation with IC50 values of about 1 µmol/l (24, 58) . PAMP20 and PAMP12 did not affect the basal activity of TH, but suppressed the activation of the enzyme caused by nicotinic stimulation. Thus, PAMP20 and PAMP12 do not exert direct actions on TH, but suppress the TH activation caused by nicotinic receptor stimulation (24, 58) .
These peptides of the PAMP20 family are endogenous peptides that regulate not only release and synthesis of catecholamines but also the expression of catecholamine-synthesizing enzymes by acting on nicotinic receptors in an autocrine manner in adrenal chromaffin cells. The expression of mRNAs for the catecholamine-synthesizing enzymes TH and DBH is increased by the stimulation of nicotinic cholinergic receptors in PC12 cells. PAMP20 but not AM suppressed the nicotine-induced mRNAs for TH and DBH (59) .
Conclusion and Perspectives
AM, PAMP20 and PAMP12 are synthesized, stored and released from adrenal chromaffin cells by regulated as well as constitutive secretory pathways (Fig. 3) . The facts that AM expression in chromaffin cells increases under hypoxic conditions and that AM expression in pheochromocytoma decreases during neuronal differentiation indicate the potential pathophysiological roles of AM in chromaffin cells. Peptides of the PAMP20 family act on nicotinic cholinergic receptors on the cell surface and modify cell functions-including catecholamine synthesis, catecholamine release, and the induction of catecholamine synthesizing enzymes-in an autocrine manner. Since the effects of AM on catecholamine release and other chromaffin cell functions were not extensive, the main function of AM may be to regulate local blood flow or remodel the vasculature by regulating the proliferation and apoptosis of vascular smooth muscle cells and endothelial cells.
The relation between high affinity binding sites for AM or PAMP20 and the physiological function in adrenal chromaffin cells remains controversial. The potencies of PAMP20 and PAMP12 in modulating physiological functions, such as by inhibiting catecholamine synthesis, or releasing and inducing production of catecholamine-synthesizing enzymes, are much weaker than their potencies in binding affinity. Finally, further studies will be needed to explore the molecular structure of receptors for PAMP20 family members. Fig. 3 
